Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1490505
This article is part of the Research Topic Precision Immunotherapy and Novel Target Discovery in Hematological Malignancy View all articles

Siglec15 in Blood system diseases： from bench to bedside

Provisionally accepted
Yu Jia Fan Yu Jia Fan 1Liangliang Sun Liangliang Sun 2Juan He Juan He 2Yutong Chen Yutong Chen 2Hongli Ma Hongli Ma 1Hai Tao Ding Hai Tao Ding 2*
  • 1 Baotou Medical College, Baotou, China
  • 2 Inner Mongolia People's Hospital, Hohhot, China

The final, formatted version of the article will be published soon.

    Inhibiting the PD-1/PD-L1 pathway using immunomodulators has demonstrated promising outcomes in clinics. Immunomodulators can effectively target immune checkpoints with a strong preference for the tumor microenvironment (TME). Besides, immunomodulators specifically target the recently discovered inhibitory immune checkpoint, sialic acid-binding immunoglobulin-like lectin (Siglec-15). Distinctive in its molecular composition, Siglec-15 has a unique molecular composition and been shown to beis highly prevalent in numerous solid tumor tissues and tumor-associated macrophages (TAMs) in human subjects., and it is notablyNotably, Siglec-15 is upregulated across various cancer types. As a result, Siglec-15 has attracted significant attention due to its exclusive nature concerning PD-L1 expression, suggesting its role in immune evasion in patients lacking PD-L1. Siglec-15 predominantly appears in certain populations and can promote tumor development by repressing T lymphocyte activation and proliferation, thereby facilitating tumor cell immune escape. Furthermore, Siglec-15 is implicated in osteoclast differentiation and bone remodeling, indicating that it is a promising target for next-generation cancer immunotherapies. Additionally, Siglec-15 can modulate immune responses to microbial infections. The current treatment strategies for hematological conditions predominantly include conventional intensive chemotherapy and transplantation methods. However, emerging immunotherapeutic approaches are increasingly recognized for their overall effectiveness, indicating that specific molecular targets should be identified. The expression of Siglec-15 within tumor cells may indicate a novel pathway for treating hematological malignancies. In this study, the biological attributes, expression patterns, and pathogenic mechanisms of Siglec-15 across various diseases were reviewed. The role of Siglec-15 in the pathogenesis and laboratory diagnosis of hematological disorders was also evaluated.

    Keywords: Siglec-15, Immune checkpoint, Osteoclasts, microbial infection, Immunotherapy, Hematological diseases

    Received: 03 Sep 2024; Accepted: 13 Nov 2024.

    Copyright: © 2024 Fan, Sun, He, Chen, Ma and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hai Tao Ding, Inner Mongolia People's Hospital, Hohhot, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.